Genomic Vision Expands Its Replication Combing Assay Service Offering

Regulatory News:

Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of transformed cells is pleased to announce the expansion of its RCA services, emphasising its ongoing commitment to developing its services offers for oncology and drug discovery.

Going beyond the standard RCA offerings and bringing tailored solutions, Genomic Vision now can provide new replication parameters like fork speed, analog ratio, fork symmetry, fork stalling and new origin firing.

Genomic Vision also offers a new Locus-RCA service, which is attracting growing interest in the scientific community, allowing the assessment of replication dynamic changes in a specific region of the genome, like oncogenes and tumor suppressor genes.

Genomic Vision is proud to deliver tailored RCA services to meet specific needs, demonstrating its commitment to providing customised genomic solutions to its partners, ultimately driving advancements in the pharmaceutical and biotechnology industries.

Total sales linked to the RCA service have risen by over 60% in a year. Indeed, between 2022 and 2023, GV achieved an outperformance in the pharmaceutical industry segment, while also seeing constant positive growth in the number of requests from academic laboratories.

Additionally, Genomic Vision's Research & Development team is actively conducting experiments to offer an even more expanded range of parameters and biomarkers for analysis within the RCA framework, further enhancing the capabilities and insights available to its clients.

Aurélien Petit, Services & Support Director at Genomic Vision, expressed his satisfaction, saying, “Having recently announced a reduction in the turnaround time for our RCA service, we are proud to be able to offer our customers new RCA parameters, while maintaining our fast and efficient service delivery. This enhancement not only underlines our commitment to meeting the ever-changing demands of this dynamic industry, but also responds to growing enquiries, reaffirming our ability to deliver cutting-edge solutions quickly.”

ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company that develops products and services for the highly accurate characterization of genome modifications. We deliver high-quality integrated genomic analysis solutions to improve quality control and bioproduction standards of advanced gene therapies at scale. Based on molecular combing technology and artificial intelligence, The Company provides robust quantitative measurements needed for high confidence characterization of transformed cell lines and prediction of cell line performance, in particular in the context of the biomanufacturing processes of cell and gene therapies. Genomic Vision’s molecular combing technology has further applications in drug development of agents targeting DNA replication and damage response mechanisms, visualizing DNA replication kinetics and telomere length maintenance. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).